Physician profile
David Lotsoff
NPI 1205807328
$913.62
in general payments reported to CMS, 2019-2025
19 companies · $471 in 2025
The $471 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.29 · 2023: $202 · 2024: $210 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $188.61 | 2022-2025 | |
| Abbvie INC. | $154.82 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $123.22 | 2023 | Zeposia |
| Gilead Sciences, INC. | $60.09 | 2024-2025 | |
| Pfizer INC. | $40.09 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $38.97 | 2024 | |
| Braintree Laboratories, INC. | $36.80 | 2025 | Suflave |
| Regeneron Healthcare Solutions, INC. | $36.62 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $32.78 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $31.13 | 2024-2025 | Entyvio |
| Lilly USA, LLC | $25.76 | 2024 | Omvoh |
| Organon LLC | $24.65 | 2024 | |
| Qol Medical, LLC | $24.52 | 2025 | Sucraid |
| Janssen Biotech, INC. | $21.72 | 2023 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.02 | 2025 | Xifaxan |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $17.82 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.01 | 2023 | |
| Daiichi Sankyo INC. | $13.18 | 2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $10.81 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lotsoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.